BI
Bio-Rad Laboratories, Inc.
BIO-B · NYSE
$385.84 +5.69% (+$20.76)
1M -0.56%
Market Cap $9.83B
P/E Ratio 44.18x
Div. Yield -
ROE 3.15%
Bulios Fair Price
$292.83
24.1% downside
Current Price
$385.84
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BIO-B is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
7/9Valuation
37 /100
Fair P/E 44.18x
P/FCF 27.83x
EV/EBITDA 19.67x
Growth
41 /100
Stable Rev. growth 6.63%
Book val. growth 18.66%
FCF growth 39.32%
Profitability
68 /100
Strong Gross margin 51.90%
FCF margin 13.64%
Net margin 8.59%
Quality
12 /100
Poor ROIC 1.54%
Asset turnover 0.25x
ROE 3.15%
Debt
91 /100
Low Debt/Equity 0.17x
Net debt/EBITDA 1.28x
Current ratio 3.14x
Stability
47 /100
Moderate Beta 1.11x
Profitable years 0
Rev. volatility 9.85%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BIO-B
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Norman D. Schwartz
Employees
7,450
Headquarters
Hercules
Upcoming events
22 OCT
Earnings
Upcoming earnings report